CORCEPT THERAPEUTICS INC financials

  1. Home
  2. Financials
  3. CORT
CORT CIK 0001088856

Source: EDGAR filings · Built 2026-06-02T02:42:56Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 141.78M 196.12M 126.54M 119.91M 167.42M 150.73M
EBITDA 45.95M 137.75M 108.32M 113.89M 125.55M 128.73M
Working Capital 319.38M 330.83M 354.13M 426.76M 218.92M 431.01M
Net Debt -114.39M -120.73M -135.40M -65.19M -77.09M -73.64M
Gross Margin 98.30% 98.39% 98.66% 98.66% 98.56% 23.87%
Operating Margin 5.88% 20.29% 22.24% 28.03% 34.01% 36.23%
Net Margin 13.09% 20.92% 22.00% 25.24% 30.74% 29.96%
Return on Equity (ROE) 15.38% 20.78% 20.95% 20.21% 29.94% 20.26%
Return on Assets (ROA) 11.91% 16.80% 17.08% 17.38% 26.55% 18.54%
Current Ratio 2.92× 3.35× 4.39× 6.89× 5.60× 10.07×
Debt-to-Equity 0.01× 0.01× 0.00× 0.00× 0.00× 0.00×
Effective Tax Rate -49.94% 12.56% 14.79% 12.71% 9.99% 19.45%
Cash Conversion Ratio 1.42× 1.40× 1.19× 1.19× 1.49× 1.43×
Accruals Ratio -0.05× -0.07× -0.03× -0.03× -0.13× -0.08×
SBC % of Revenue 11.10% 9.09% 10.15% 10.56% 11.73% 9.48%
CapEx Coverage 672.97× 91.30× 911.37× 291.34× 357.98× 122.75×
Free Cash Flow Per Share $1.18 $1.73 $1.13 $1.03 $1.33 $1.21

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 42.44× 40.97× 34.55× 23.34× 22.25× 30.78×
P/FCF 29.45× 29.16× 28.68× 19.64× 14.90× 21.55×
FCF Yield 3.40% 3.43% 3.49% 5.09% 6.71% 4.64%
EV / EBITDA 77.77× 37.58× 29.76× 18.66× 16.09× 23.15×
P/S 4.84× 7.85× 6.96× 5.45× 5.73× 8.63×
P/B 5.69× 7.79× 6.63× 4.36× 5.58× 5.84×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 761.41M 675.04M 482.38M 401.86M 365.98M 353.87M
Cost of Goods and Services Sold 12.98M 10.88M 6.48M 5.38M 5.28M 5.58M
Gross Profit — — — — — 84.48M
Research and Development Expense 254.91M 246.89M 184.35M 130.99M 113.86M 114.76M
Selling, General and Administrative Expense 448.73M 280.32M 184.26M 152.85M 122.36M 105.33M
Operating Income (Loss) 44.80M 136.95M 107.28M 112.63M 124.48M 128.20M
Income Tax Expense (Benefit) -33.19M 20.28M 18.42M 14.77M 12.49M 25.59M
Net Income (Loss) Attributable to Parent 99.65M 141.21M 106.14M 101.42M 112.51M 106.01M
Earnings Per Share, Basic $0.95 $1.35 $1.02 $0.95 $0.97 $0.92
Weighted Average Number of Shares Outstanding, Basic 103.86M 103.23M 103.56M 106.79M 115.65M 115.41M
Earnings Per Share, Diluted $0.82 $1.23 $0.94 $0.87 $0.89 $0.85
Weighted Average Number of Shares Outstanding, Diluted 119.99M 113.48M 111.74M 115.97M 125.96M 124.19M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 120.50M 127.67M 135.55M 66.33M 77.62M 76.19M
Assets, Current 485.46M 471.60M 458.64M 499.25M 266.46M 478.50M
Assets 836.65M 840.55M 621.52M 583.43M 423.76M 571.73M
Liabilities, Current 166.09M 140.77M 104.50M 72.49M 47.54M 47.49M
Liabilities 188.85M 160.96M 114.81M 81.59M 47.95M 48.39M
Stockholders' Equity Attributable to Parent 647.80M 679.59M 506.70M 501.84M 375.81M 523.34M
Common Stock, Shares, Outstanding 105.97M 105.11M 103.41M 107.83M 105.94M 116.73M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 142.00M 198.29M 126.68M 120.32M 167.89M 151.97M
Payments to Acquire Property, Plant, and Equipment 211.00K 2.17M 139.00K 413.00K 469.00K 1.24M
Net Cash Provided by (Used in) Investing Activities 69.76M -177.60M 90.91M -114.33M 136.13M -119.26M
Payments for Repurchase of Common Stock 172.91M 15.66M 0 0 — 9.95M
Net Cash Provided by (Used in) Financing Activities -220.37M -28.35M -148.72M -17.28M -302.59M 12.21M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CORT CIK 0001088856), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AI

C3.AI, INC.

FRAF

FRANKLIN FINANCIAL SERVICES CORPORATION

PEW

GrabAGun Digital Holdings Inc.